RxDoctor Payments Data

Sabeena Ramrakhiani, MD

Cardiovascular Disease · Fort Wayne, INNPI 1336314806

Payments from drug & device makers

$8,183in general payments, 2019–2025

Across 251 payments — averaging $32.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$4K
  • Johnson & Johnson$1K
  • AstraZeneca$540
  • Novartis$424
  • Amgen$376
  • Boehringer Ingelheim$307
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$7269%
  • Speaking & faculty fees$2,90035%
  • Travel & lodging$380%
  • Food & beverage$4,39854%
  • Education$1211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,183 in reported general payments places this provider in the 65th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$104,741
Medicare patients
1,114
Services billed
1,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban484$556,658
EntrestoSacubitril/Valsartan215$251,802
XareltoRivaroxaban192$241,449
Repatha SureclickEvolocumab260$198,101
JardianceEmpagliflozin108$124,388
CamzyosMavacamten13$104,660
FarxigaDapagliflozin Propanediol55$60,138
Praluent PenAlirocumab69$48,515
MultaqDronedarone Hcl14$25,672
VerquvoVericiguat14$24,745
Repatha PushtronexEvolocumab18$23,128
VascepaIcosapent Ethyl23$19,236
NexletolBempedoic Acid22$10,073
Ranolazine ErRanolazine110$9,829
Metoprolol Succinate539$6,133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$162$556,658484 claims
NovartisEntresto$424$251,802215 claims
Johnson & JohnsonXarelto$1,309$241,449192 claims
Boehringer IngelheimJardiance$307$124,388108 claims
E.r. Squibb & Sons, L.L.C.Camzyos$4,195$104,66013 claims
AstraZenecaFarxiga$540$60,13855 claims
Sanofi-aventis U.S. LLCMultaq$126$25,67214 claims
MerckVerquvo$305$24,74514 claims
Esperion Therapeutics, Inc.Nexletol$34$10,07322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →